La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Jiuzhou Pharmaceutical Crescita futura

Future criteri di controllo 2/6

Zhejiang Jiuzhou Pharmaceutical prevede che gli utili e i ricavi cresceranno rispettivamente di 16.4% e 14.7% all'anno. Si prevede che l'EPS crescerà di 16.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 14.9% in 3 anni.

Informazioni chiave

16.4%

Tasso di crescita degli utili

16.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.9%
Tasso di crescita dei ricavi	14.7%
Rendimento futuro del capitale proprio	14.9%
Copertura analitica	Good
Ultimo aggiornamento	20 May 2024

Aggiornamenti recenti sulla crescita futura

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Recent updates

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Jun 13

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

May 24

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

May 01

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28

Previsioni di crescita degli utili e dei ricavi

SHSE:603456 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	7,954	1,556	N/A	2,010	4
12/31/2025	7,251	1,513	N/A	1,747	5
12/31/2024	6,294	1,259	N/A	1,574	5
3/31/2024	5,248	989	-185	767	N/A
12/31/2023	5,523	1,033	431	1,360	N/A
9/30/2023	5,649	1,145	311	1,135	N/A
6/30/2023	5,745	1,075	524	1,386	N/A
3/31/2023	5,823	994	518	1,300	N/A
12/31/2022	5,445	921	512	1,226	N/A
9/30/2022	5,432	904	787	1,490	N/A
6/30/2022	5,150	827	450	1,098	N/A
3/31/2022	4,581	747	448	1,050	N/A
12/31/2021	4,063	634	98	678	N/A
9/30/2021	3,906	614	-71	456	N/A
6/30/2021	3,507	526	115	494	N/A
3/31/2021	3,112	443	-59	330	N/A
12/31/2020	2,647	381	85	400	N/A
9/30/2020	2,404	341	308	612	N/A
6/30/2020	2,167	265	11	357	N/A
3/31/2020	2,010	227	206	529	N/A
12/31/2019	2,017	238	234	554	N/A
9/30/2019	1,952	198	43	357	N/A
6/30/2019	1,800	171	127	406	N/A
3/31/2019	1,785	149	114	363	N/A
12/31/2018	1,862	157	34	265	N/A
9/30/2018	1,752	128	186	325	N/A
6/30/2018	1,839	163	171	282	N/A
3/31/2018	1,798	157	98	215	N/A
12/31/2017	1,717	148	N/A	275	N/A
9/30/2017	1,696	139	N/A	157	N/A
6/30/2017	1,694	147	N/A	177	N/A
3/31/2017	1,697	116	N/A	85	N/A
12/31/2016	1,653	111	N/A	137	N/A
9/30/2016	1,559	118	N/A	83	N/A
6/30/2016	1,500	126	N/A	44	N/A
3/31/2016	1,458	197	N/A	73	N/A
12/31/2015	1,445	200	N/A	141	N/A
9/30/2015	1,432	195	N/A	110	N/A
6/30/2015	1,349	170	N/A	98	N/A
3/31/2015	1,325	142	N/A	184	N/A
12/31/2014	1,286	133	N/A	10	N/A
9/30/2014	1,229	155	N/A	138	N/A
12/31/2013	1,310	166	N/A	204	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 603456 ( 16.4% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 603456 ( 16.4% all'anno) cresceranno più lentamente rispetto al mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 603456 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 603456 ( 14.7% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 603456 ( 14.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 603456 sarà basso tra 3 anni ( 14.9 %).

Zhejiang Jiuzhou Pharmaceutical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Price target decreased to CN¥50.46

Price target decreased to CN¥63.18

Price target increased to CN¥69.15

Price target raised to CN¥22.95

Recent updates

Dividend of CN¥0.50 announced

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Now 22% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in 1Q 2023)

Now 21% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Price target decreased to CN¥50.46

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Price target decreased to CN¥63.18

Less than half of directors are independent

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥69.15

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

New 90-day low: CN¥30.48

Investor sentiment deteriorated over the past week

New 90-day high: CN¥38.24

New 90-day high: CN¥35.97

New 90-day low: CN¥29.09

Third quarter earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2020 Results on Oct 22, 2020

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 1 billion in funding

Price target raised to CN¥22.95

First half earnings released

Earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita